aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in 1998, PTC Therapeutics, Inc. is a US-based pharmaceutical company dedicated to developing orally administered, small-molecule drugs targeting genetic disorders, oncology, and infectious diseases. The company's core mission is to discover and commercialize innovative treatments that address unmet medical needs, improving the quality of life for patients worldwide. PTC Therapeutics focuses on creating therapies that are both effective and accessible, aiming to transform the landscape of rare disease treatment.
Notable figures affiliated with PTC Therapeutics include Stuart W. Peltz, a co-founder and key leader in the company's strategic direction. The company has attracted significant investment from prominent venture capital firms and institutional investors. Key achievements include the development and approval of several groundbreaking therapies, such as Translarna for Duchenne muscular dystrophy. PTC Therapeutics' impact is evident in its contributions to advancing medical science and providing hope to patients with rare and challenging conditions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals
Technology
Biotech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
Global
When was PTC Therapeutics founded?
PTC Therapeutics was founded in 1998.
Where is PTC Therapeutics's headquarters located?
PTC Therapeutics's headquarters is located in London, GB.
When was PTC Therapeutics's last funding round?
PTC Therapeutics's most recent funding round was for $1B (USD) in October 2022.
How many employees does PTC Therapeutics have?
PTC Therapeutics has 1402 employees as of Feb 6, 2024.
How much has PTC Therapeutics raised to-date?
As of July 05, 2023, PTC Therapeutics has raised a total of $1.6B (USD) since Oct 27, 2022.
Add Comparison
Total Raised to Date
$1.6B
USD
Last Update Oct 27, 2022
Last Deal Details
$1B
USD
Oct 27, 2022
Post Ipo Equity
Total Employees Over Time
1.4k
As of Feb 2024
PTC Therapeutics Address
London,
Greater London
ec4a 3bz
United Kingdom
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts